Issue 321

Our Phage Picks for Aug 2025

It’s Phage Picks time! This week, we highlight some new mind-expanding papers — one showing how phage killing might train the immune system like vaccines, one unpacking how temperate phages rewrite bacterial flagella with RNA-guided tools, and another showing how an explainable machine learning model can teach us about the biology of our bacterial strains.

Community digest1alert5updates2jobs2posts

Phage alert

Urgent need for Cutibacterium granulosum phages for a patient in Australia

July 30, 2025

We are urgently seeking Cutibacterium granulosum phages (or any Cutibacterium-specific phages) for a patient with a vascular graft infection in Australia. If you can help, please reach out!

Ways to help at this stage:

  • By sending your phages (or lysins!) for testing on the patient's strains
  • By receiving the patient's strain and testing your phages
  • By helping spread the word about this request
  • By providing us with names/email addresses of labs you think we should contact

Please email staff@phage.directory if you can help in any way, or if you would like further details/clarification.

Let’s make a difference, Phage Directory

Phage TherapyVascular graft

Updates

Sophia Zborowsky (Institut Pasteur) and colleagues published a new paper on macrophage interference with phage therapy efficacy, showing alveolar macrophages reduce phage density through phagocytosis and adsorption inhibition, limiting therapeutic efficacy against Pseudomonas aeruginosa pneumonia in mice.

Research paperPhage-immune interactionsPhage therapy

Mengyu Li (University of Sydney) and colleagues published a new paper on long-term stability of inhalable phage powder formulations, showing spray-dried phage powders maintained viability over four years with 0.97-2.49 log titer reduction, with higher lactose concentrations providing better biological preservation despite decreased aerosol performance.

Research paperPhage storage stabilityPhage delivery

Zainab Dere (Florida State University) and colleagues published a new paper on optimal phage therapy control strategies, showing mathematically that phages can suppress antibiotic-resistant bacteria and offering a clinically translatable implementation framework.

Research paperMathematical modeling

Naïma Madi (McGill University) and colleagues published a new paper on ranking phage predation as dehydration determinant, showing the phage-to-pathogen ratio is a top classifier of severe dehydration in cholera patients, just behind age and admission site.

Research paperCholera

Martin Plymoth (Westmead Hospital, Australia) and colleagues published a new paper on Australian physician attitudes toward phage therapy, showing 97% of infectious disease specialists would consider using phage therapy meeting safety guidelines, with preferences for Gram-negative pathogens and cystic fibrosis applications.

SurveyPhage therapyInfectious disease specialists

Jobs

August 7, 2025

Invitris is hiring a Senior Scientist, to develop next-gen protein-based tech (like cell-free phage production!) in Munich.

Senior ScientistSynthetic biology

August 7, 2025

ATCC (Gaithersburg, Maryland), the iconic nonprofit biological resources and standards organization, is hiring a Scientist, Biomedical Genomics, to contribute to the implementation and computational analysis of 'omics data and next-generation sequencing (NGS) projects.

Culture collectionScientist

Community board

August 7, 2025

Fatma Abdelrahman, founder of Women in Phage, invites phage scientists to complete her survey on women’s experiences and challenges in phage research. Share your insights to shape future support and inspire the next generation.

SurveyWomen in Phage

August 7, 2025

Phage Australia and colleagues has announced ISO 9001:2015 certification for its therapeutic phage biobank-to-bedside pipeline! ISO 9001 certification not only enhances Phage Australia's operational efficiency, but also ensures their products meet the rigorous safety and quality requirements required for phage therapy.

MilestoneISO 9001Phage therapy

Hi everyone,

We found some interesting papers for this month’s Picks!

My biggest takeaway is that the more we learn about how phages, bacteria, and the immune system interact, the more we realize how intricate and complex the entire system actually is, and that there’s a lot more to uncover and understand.

~ Jan

Phage-induced protection against lethal bacterial reinfection

What is it about?

This study shows that phage therapy does more than just kill bacteria — it also trains the immune system to fight off future infections! Researchers used mice infected with a lethal dose of E. coli (a sepsis model) and treated them with a therapeutic phage called HP3. Not only did the phage cure the initial infection, but when they re-infected the same mice 4 weeks later (without giving them any more phage), an amazing 93% survived what should have been a lethal dose. The protection seems to come from phage lysis of the bacteria and releasing antigens that the immune system can learn to recognize, kind of like a personalized vaccine made from the patient's own infection.

Why I'm excited about it:

I think this is huge! We've always thought of phages as just bacterial killers, and thought about their immune responses as an annoyance if anything, but this research shows they might be functional as dual-action therapeutics — both treatment AND vaccination rolled into one. The protection was incredibly strong (reducing bacterial loads by a billion-fold!) and didn't require any additional phage treatment (and the original phages had long gone!). The fact that this worked with two completely different phages (though HP3 was best) suggests this might be a broader phenomenon we can harness — and that some phages might have this property more than others (and maybe we should pick those for future therapy).

~ Jess

Paper: https://www.pnas.org/doi/10.1073/pnas.2423286122

Xing, Y., Hernandez Santos, H. J., Qiu, L., Ritter, S. R., Zulk, J. J., Lahowetz, R., Patras, K. A., Terwilliger, A. L., & Maresso, A. W. (2025). Phage-induced protection against lethal bacterial reinfection. Proceedings of the National Academy of Sciences, 122(22), e2423286122.

Temperate phages enhance host fitness via RNA-guided flagellar remodeling

What is it about?

This study reveals how certain temperate phages (called Flagellin Remodeling prophages or FRφ) use RNA-guided systems to completely redesign their bacterial host's flagella. The researchers found that these phages produce proteins called TldR that work like molecular switches to turn off the host's normal flagellin, and replace it with the phage's own version. This flagellar redesign gives the bacteria extra properties: they swim better, hide from the immune system more effectively, and colonize the gut more successfully. Using cryo-electron microscopy, the team showed that the phage-modified flagella have completely different structures than normal ones, explaining why they work so much better.

Why I'm excited about it:

This paper actually blows my mind a bit, especially as I studied flagella and (Campylobacter) phage interactions in my PhD — I would have been so psyched to see this then! At the time it felt like it would be crazy to propose that phage were having a hand in what the flagella did… Also, the fact that these RNA-guided systems evolved independently multiple times suggests this is not a fluke and could be a broadly useful strategy. Very cool to think that phages could be helping their bacterial hosts become better at surviving in real-world environments like our guts. I wonder how this might lead to new therapeutic approaches where we could use phages to modify bacteria in beneficial ways.

~ Jess

Preprint: https://www.biorxiv.org/content/10.1101/2025.07.22.666180v1

Walker, M. W. G., Richard, E., Wiegand, T., Wang, J., Yang, Z., Casas-Ciniglio, A. A., Hoffmann, F. T., Shahnawaz, H., Gaudet, R. G., Arpaia, N., Fernández, I. S., & Sternberg, S. H. (2025). Temperate phages enhance host fitness via RNA-guided flagellar remodeling. bioRxiv.

Predicting clinical outcome of Escherichia coli O157:H7 infections using explainable Machine Learning

What is it about?

The authors in this paper collected a bunch of shiga-toxin producing E.coli (STEC) genomes from across the UK, and used two machine learning approaches to predict clinical outcomes of the STEC infections. Using both Random Forest and XGBoost, they were able to correctly predict which isolates were high risk, in what would otherwise have been low-risk lineages.

The researchers were then able to connect the predictions back to what genomic elements led to the predictions (which included phage-encoded elements, and others).

Why I'm excited about it:

I think papers like this show that you can use prediction models to see your phage and isolate bank in different ways, and find new patterns and connections. In this paper, the models found potentially novel intergenic features as highlighted by their “explainable” models (as in, the prediction tells you which features, e.g. k-mers in this case, might be a reason for its high prediction rate). So using methods like this is kind of like presenting key ring of the most viable keys (out of thousands), but you still have to check them. Some doors are already opened, like stx2a in this case, but others could open doors you didn’t even know existed!

~ Jan

Paper: https://www.medrxiv.org/content/medrxiv/early/2025/06/06/2025.06.05.25329036.full.pdf

Paganini, J. A., Khatun, S., McAteer, S., Cowley, L., Greig, D. R., Gally, D. L., Jenkins, C., & Dallman, T. J. (2025). Predicting clinical outcome of Escherichia coli O157:H7 infections using explainable machine learning. medRxiv.

Phage Biology and ResearchTechBioPhage Therapy Applications

Jessica Sacher, PhD

Phage Directory; Stanford University; Bollyky Lab

I'm a co-founder of Phage Directory and have a PhD in Microbiology from the University of Alberta (I studied Campylobacter phage biology). For Phage Directory, I help physicians find phages for their patients, and I'm always trying to find new ways to help the phage field grow (especially through connecting people and highlighting awesome stuff I see happening in the field).

I spent 2022-2024 as a postdoc in Jon Iredell's group at Westmead Institute for Medical Research in Sydney, Australia, helping get Phage Australia off the ground. I helped set up workflows for phage sourcing, biobanking, diagnostics, production, purification and QC of therapeutic phage batches, and helped build data collection systems to track everything we did. We treated more than a dozen patients in our first year, and I'm so proud of that!

As of 2024, I joined the Bollyky lab at Stanford University as a Staff Scientist, where I'm focused on phage engineering and delivery (to both microbial and human cells) and hydrogel-embedded phage cocktail development for wounds!

All 147 issues by Jessica →

Jan Zheng, MHCI

Phage Directory (Co-founder); NVIDIA

I'm Jan, the other half of Phage Directory, and co-write Capsid & Tail.

Previously, I did data work at Phage Australia / Westmead Institute, where I built the biobank databases, data systems, and bioinformatics workflows for the clinical trial

I have a background in computer science and human-computer interaction, and I'm currently full-time at building the agentic layer for science at Nvidia.

All 80 issues by Jan →